Ryan Mee, CEO of Fulcrum Metals, reviews FY23 and progress on the Gold Tailings Hub in Canada. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksNovacyt Regulatory News (NCYT)

Share Price Information for Novacyt (NCYT)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 71.60
Bid: 70.20
Ask: 73.00
Change: 0.00 (0.00%)
Spread: 2.80 (3.989%)
Open: 71.60
High: 0.00
Low: 0.00
Prev. Close: 71.60
NCYT Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Liquidity Agreement Update and Total Voting Rights

2 Mar 2020 13:15

RNS Number : 7180E
Novacyt S.A.
02 March 2020
 

 

Liquidity Agreement Monthly Update andTotal Voting Rights

 

Paris, France and Camberley, UK - 2 March 2020 - Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, today announces its monthly update in relation to ordinary shares traded under its ongoing liquidity agreement with Invest Securities SA (the "Liquidity Agreement"). The Liquidity Agreement is governed by French law and is further summarised in the 'notes for editors' section below.

 

During the period from 1 February to 29 February 2020, Invest Securities purchased 95,050 ordinary shares at a maximum price of €1.80 and a minimum price of €0.40 and sold 121,516 ordinary shares at a maximum price of €1.94 and a minimum price of €0.49 under the Liquidity Agreement. The total number of ordinary shares in the Company, which are held in treasury as at close of business on 29 February 2020, is 7,050.

 

Total Voting Rights

 

The total number of ordinary shares in the Company is 67,673,567 following the issue of equity announced on 19 February 2020. This figure may be used by shareholders as the denominator for calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company pursuant to Article L. 223-7 of the French Commercial Code and the Company's Articles. The Company is not subject to the disclosure guidance and transparency rules made by the Financial Conduct Authority under Part VI of FSMA.

 

 

For further information, please refer to www.novacyt.com or contact:

 

Novacyt SA

Graham Mullis, Chief Executive Officer

Anthony Dyer, Chief Financial Officer

+44 (0)1276 600081

 

SP Angel Corporate Finance LLP (Nominated Adviser and Broker)

Matthew Johnson / Charlie Bouverat (Corporate Finance)

Vadim Alexandre / Rob Rees (Corporate Broking)

+44 (0)20 3470 0470

 

FTI Consulting (International)

Victoria Foster Mitchell / Mary Whittow

+44 (0)20 3727 1000

victoria.fostermitchell@fticonsulting.com / mary.whittow@fticonsulting.com

 

FTI Consulting (France)

Arnaud de Cheffontaines

+33 (0)147 03 69 47

arnaud.decheffontaines@fticonsulting.com 

 

 

About Novacyt Group

 

The Novacyt Group is an international diagnostics business generating an increasing portfolio of in vitro and molecular diagnostic tests. Its core strengths lie in diagnostics product development, commercialisation, contract design and manufacturing. The Company's lead business units comprise of Primerdesign and Lab21 Products, supplying an extensive range of high quality assays and reagents worldwide. The Group directly serves oncology, microbiology, haematology and serology markets as do its global partners, which include major corporates.

 

Further information on the Liquidity Agreement

On 12 September 2016, the Company and Invest Securities entered into the Liquidity Agreement pursuant to which Invest Securities provides liquidity services in relation to the ordinary shares to the Company. Invest Securities may purchase ordinary shares on behalf of the Company under the agreement, subject to approval from Shareholders as to the price at which ordinary shares can be brought back and the aggregate amount that the Company may provide to Invest Securities to purchase such ordinary shares.

 

Shareholder approval was granted at the Shareholders' meeting held on 27 June 2017 for the purchase of ordinary shares by Invest Securities under the agreement at a maximum purchase price per ordinary shares of €8.10 for an aggregate maximum purchase price of €100,000 and for 18 months from the date of the approval. Under the agreement, Invest Securities must act completely independently of the Company and the Company must not communicate with the employees of Invest Securities who are responsible for performing the agreement. Invest Securities is paid €10,000 per annum for its services under the liquidity agreement. The agreement has an initial term of two years, with a rolling extension of one year thereafter. The agreement can be terminated by either party at the end of each such period subject to two months' prior notice. The Liquidity Agreement is governed by French law. Ordinary shares purchased by Invest Securities are either cancelled or held as treasury shares (which are non-voting and do not rank for dividends).

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
TVRKKBBKNBKDONK
Date   Source Headline
12th Mar 202111:00 amRNSHoldings in Company
1st Mar 20212:30 pmRNSLiquidity Agreement and Total Voting Rights
24th Feb 20216:30 pmRNSCorrection: Research and Development Update
24th Feb 20217:00 amRNSResearch and Development Update
2nd Feb 20217:00 amRNSLaunch of PCR assay portfolio
1st Feb 202112:30 pmRNSTotal Voting Rights
29th Jan 20217:00 amRNSFull Year 2020 Trading Update
26th Jan 20215:30 pmRNSHolding(s) in Company
13th Jan 202112:30 pmRNSHoldings in Company
5th Jan 20217:00 amRNSExecutive Management and Proposed Board Changes
4th Jan 20212:15 pmRNSLiquidity Agreement and Total Voting Rights
21st Dec 20207:00 amRNSNew COVID-19 variant
14th Dec 20207:00 amRNSTests for new strains of COVID-19 and avian flu
2nd Dec 20201:15 pmRNSHolding(s) in Company
1st Dec 20202:15 pmRNSLiquidity Agreement and Total Voting Rights
18th Nov 20206:20 pmRNSDirector/PDMR Shareholding
16th Nov 20207:00 amRNSR&D Update
13th Nov 20206:05 pmRNSDirector/PDMR Shareholding
13th Nov 20207:00 amRNSDirector/PDMR Shareholding
12th Nov 20207:00 amRNSDirector/PDMR Shareholding
11th Nov 202011:05 amRNSDirector/PDMR Shareholding
2nd Nov 20201:00 pmRNSLiquidity Agreement and Total Voting Rights
28th Oct 20204:41 pmRNSSecond Price Monitoring Extn
28th Oct 20204:35 pmRNSPrice Monitoring Extension
28th Oct 20202:06 pmRNSSecond Price Monitoring Extn
28th Oct 20202:00 pmRNSPrice Monitoring Extension
15th Oct 202011:30 amRNSAcquisition of IT-IS International Ltd
2nd Oct 20201:30 pmRNSLiquidity Agreement and Total Voting Rights
29th Sep 20205:00 pmRNSResult of AGM
29th Sep 202011:05 amRNSSecond Price Monitoring Extn
29th Sep 202011:00 amRNSPrice Monitoring Extension
29th Sep 20209:05 amRNSSecond Price Monitoring Extn
29th Sep 20209:00 amRNSPrice Monitoring Extension
29th Sep 20207:00 amRNSLaunch of COVID-19 antibody test
29th Sep 20207:00 amRNSNew UK DHSC Contract
28th Sep 20203:00 pmRNSAppointment of ODDO BHF
21st Sep 202011:05 amRNSSecond Price Monitoring Extn
21st Sep 202011:00 amRNSPrice Monitoring Extension
18th Sep 20207:00 amRNSAGM Voting
17th Sep 20207:00 amRNSHalf year 2020 results
16th Sep 20207:00 amRNSAppointment of Joint Broker
4th Sep 20207:00 amRNSLaunch of two gene COVID-19 test
1st Sep 20202:00 pmRNSLiquidity Agreement and Total Voting Rights
27th Aug 20207:00 amRNSLaunch of respiratory test panel
19th Aug 20201:15 pmRNSNotice of AGM
3rd Aug 20201:30 pmRNSLiquidity Agreement and Total Voting Rights
27th Jul 20207:00 amRNSR&D Update
22nd Jul 20204:41 pmRNSSecond Price Monitoring Extn
22nd Jul 20204:36 pmRNSPrice Monitoring Extension
22nd Jul 20203:30 pmRNS2000 patient trial using Novacyt's testing system

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.